Gary Eichenbaum

Gary Eichenbaum

Auto-generated profile, based on publicly available information

Gary Eichenbaum

Johnson & Johnson, New Brunswick, NJ, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 1999 in Macromolecules
Verified
Journal Article
Closed access
GEGary M. Eichenbaum
Gary M. Eichenbaum
PKPatrick F. Kiser
Patrick F. Kiser
ADAndrey Dobrynin
Andrey Dobrynin
SSSidney A. Simon
Sidney A. Simon
DNDavid Needham
David Needham

1 October 2009 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
GEG. Eichenbaum
G. Eichenbaum
MJM. Johnson
M. Johnson
DKD. Kirkland
D. Kirkland
POP. O’nEill
P. O’nEill
SSS. Stellar
S. Stellar
ATA. Tonelli
A. Tonelli

1 July 1998 in Macromolecules
Verified
Journal Article
Closed access
GEGary M. Eichenbaum
Gary M. Eichenbaum
PKPatrick F. Kiser
Patrick F. Kiser
SSSidney A. Simon
Sidney A. Simon
DNDavid Needham
David Needham

15 June 2012 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
RRRobert B Raffa
Robert B Raffa
HBHelmut Buschmann
Helmut Buschmann
TCThomas Christoph
Thomas Christoph
GEGary Eichenbaum
Gary Eichenbaum
WEWerner Englberger
Werner Englberger
TTThomas M Tzschentke
Thomas M Tzschentke
Introduction: Many opioid analgesics share common structural elements; however, minor differences in structure can result in major differences in pharmacological activity, pharmacokinetic profile, and clinical efficacy and tolerability. Areas covered: This review compares and contrasts the chemistry, pharmacodynamics, pharmacokinetics, and CNS ‘functional activity' of tapentadol and tramadol, responsible for their individual clinical utilities. Expert opinion: The distinct properties of tapentadol and tramadol generate different CNS functional activities, making each drug the prototype of different classes of opioid/nonopioid analgesics. Tramadol's analgesia derives from relatively weak µ-opioid receptor (MOR) agonism, plus norepinephrine and serotonin reuptake inhibition, provided collectively by the enantiomers of the parent drug and a metabolite that is a stronger MOR agonist, but has lower CNS penetration. Tapentadol's MOR agonist activity is several-fold greater than tramadol's, with prominent norepinephrine reuptake inhibition and minimal serotonin effect. Accordingly, tramadol is well-suited for pain conditions for which a strong opioid component is not needed—and it has the benefit of a low abuse potential; whereas tapentadol, a schedule-II controlled substance, is well-suited for pain conditions requiring a strong opioid component—and it has the benefit of greater gastrointestinal tolerability compared to classical strong opioids. Both drugs offer distinct and complementary clinical options.

1 December 1999 in Macromolecules
Verified
Journal Article
Closed access
GEGary M. Eichenbaum
Gary M. Eichenbaum
PKPatrick F. Kiser
Patrick F. Kiser
DSDipak Shah
Dipak Shah
SSSidney A. Simon
Sidney A. Simon
DNDavid Needham
David Needham

27 April 2000 in Macromolecules
Verified
Journal Article
Closed access
GEGary M. Eichenbaum
Gary M. Eichenbaum
PKPatrick F. Kiser
Patrick F. Kiser
DSDipak Shah
Dipak Shah
WMWilliam P. Meuer
William P. Meuer
DNDavid Needham
David Needham
SSSidney A. Simon
Sidney A. Simon